WO2012064301A3 - Physically improved tablet formulations - Google Patents

Physically improved tablet formulations Download PDF

Info

Publication number
WO2012064301A3
WO2012064301A3 PCT/TR2011/000243 TR2011000243W WO2012064301A3 WO 2012064301 A3 WO2012064301 A3 WO 2012064301A3 TR 2011000243 W TR2011000243 W TR 2011000243W WO 2012064301 A3 WO2012064301 A3 WO 2012064301A3
Authority
WO
WIPO (PCT)
Prior art keywords
tablet formulations
improved tablet
physically improved
receptor antagonist
leukotriene receptor
Prior art date
Application number
PCT/TR2011/000243
Other languages
French (fr)
Other versions
WO2012064301A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012064301A2 publication Critical patent/WO2012064301A2/en
Publication of WO2012064301A3 publication Critical patent/WO2012064301A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to physically improved tablet formulations of a leukotriene receptor antagonist and combinations of the leukotriene receptor antagonist with an H1- antihistaminic which are effective in prevention and/or treatment of allergic and inflammatory diseases of the skin or upper and lower respiratory tracts and relieving the symptoms thereof.
PCT/TR2011/000243 2010-11-11 2011-11-03 Physically improved tablet formulations WO2012064301A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (en) 2010-11-11 2010-11-11 Tablet formulations with improved physical properties
TR2010/09398 2010-11-11

Publications (2)

Publication Number Publication Date
WO2012064301A2 WO2012064301A2 (en) 2012-05-18
WO2012064301A3 true WO2012064301A3 (en) 2012-07-19

Family

ID=45446164

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000243 WO2012064301A2 (en) 2010-11-11 2011-11-03 Physically improved tablet formulations
PCT/TR2011/000247 WO2012064305A2 (en) 2010-11-11 2011-11-03 Formulations with improved physical characteristics

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000247 WO2012064305A2 (en) 2010-11-11 2011-11-03 Formulations with improved physical characteristics

Country Status (2)

Country Link
TR (1) TR201009398A2 (en)
WO (2) WO2012064301A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130050952A (en) 2010-06-16 2013-05-16 브루스 챈들러 메이 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
RU2677649C2 (en) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Pharmaceutical compositions of montelucast and levocetirisine
AU2014249456B2 (en) 2013-03-13 2018-08-09 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2016512262A (en) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Use of levocetirizine and montelukast in the treatment of vasculitis
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP6488003B2 (en) 2014-04-25 2019-03-20 アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー Stable montelukast solution
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
PL3222279T3 (en) 2016-03-21 2022-05-09 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
WO2017210417A1 (en) * 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
KR102110304B1 (en) * 2017-06-30 2020-05-14 한미약품 주식회사 Composite chewable tablet comprising levocetirizine and montelukast with improved stability and adaptability of taking medicine and a process for the preparation thereof
MX2018011699A (en) * 2018-09-26 2019-07-24 Federico Amezcua Amezcua A synergistic pharmaceutical composition of leukotriene receptor antagonist and a histamine h1 inverse agonist.
JP2022516729A (en) * 2019-01-10 2022-03-02 ジャンイン ムコケア ファーマシューティカル カンパニー，リミテッド New formulation containing leukotriene receptor antagonist
JP2024514989A (en) * 2021-10-21 2024-04-03 ハン ファ ファーマ カンパニー、リミテッド Film-coated tablets with improved stability containing montelukast or a pharmaceutically acceptable salt thereof and levocetirizine or a pharmaceutically acceptable salt thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077135A1 (en) * 2005-12-30 2007-07-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
US20090124657A1 (en) * 2007-08-14 2009-05-14 Ramesh Kappala Pharmaceutical compositions comprising montelukast
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (en) 1981-02-06 1988-08-08 Ucb Sa Process for the preparation of therapeutically active 2- [4- (diphenylmethyl) -1-piperazinyl] -acetic acid or its amide
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
EP0480717B1 (en) 1990-10-12 1998-04-15 Merck Frosst Canada Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
DE10199031I2 (en) 1992-09-24 2004-09-23 Sepracor Inc Use of (-) cetrizine to treat allergic rhinitis and asthma.
AU2003264859A1 (en) 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
JP2009526047A (en) 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド Stable pharmaceutical formulation of Montelukast sodium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077135A1 (en) * 2005-12-30 2007-07-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
US20090124657A1 (en) * 2007-08-14 2009-05-14 Ramesh Kappala Pharmaceutical compositions comprising montelukast
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
WO2012064305A3 (en) 2012-08-09
TR201009398A2 (en) 2012-05-21
WO2012064301A2 (en) 2012-05-18
WO2012064305A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
WO2012064301A3 (en) Physically improved tablet formulations
IL265774B (en) Diagnosis, prevention and treatment of diseases of the joint
LTC2435432I2 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
IL257581A (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
BR112013015855A2 (en) compound, use of a compound, methods of prevention, treatment, amelioration or prophylaxis of physiological disorders or diseases, and treatment or amelioration of cosmetic indications; and, pharmaceutical composition.
BR112013015859A2 (en) compound, use of a compound, methods of prevention, treatment, amelioration or prophylaxis of physiological disorders or diseases, and treatment or amelioration of cosmetic indications, and, pharmaceutical composition
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
EP2729148A4 (en) Compositions and methods for treatment of symptoms in parkinson's disease patients
WO2012061390A3 (en) Therapeutic compositions and methods
GB2496800B (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2014007972A3 (en) Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
WO2012047951A3 (en) Human lung stem cells and uses thereof
IL230957A0 (en) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EP2437780A4 (en) Therapeutic compositions and methods for the prevention of autoimmune diseases
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
WO2012066103A3 (en) Inhibitors of apoptosis and uses thereof
GB201215873D0 (en) Compositions and methods relating to the treatment of allergy and allergic diseases
HK1197235A1 (en) Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
PT2603238E (en) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
WO2011159254A3 (en) The use of des-aspartate-angiotensin i in inflammation-related pathologies and diseases
HUE040124T2 (en) Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain
WO2011104415A3 (en) Ash of coffee husks after roasting and separation from the coffee kernel for use as topical medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805266

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011805266

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011805266

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 11805266

Country of ref document: EP

Kind code of ref document: A2